bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of “Hold” from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been given an average recommendation of “Hold” by the eleven brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $3.03.

A number of research firms have recently issued reports on BLUE. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and reduced their price target for the company from $3.00 to $0.50 in a research note on Friday, November 15th. Wells Fargo & Company lowered their price target on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 25th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Barclays dropped their target price on bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. Finally, Robert W. Baird reduced their price target on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th.

bluebird bio Price Performance

BLUE stock opened at $0.41 on Friday. bluebird bio has a 52-week low of $0.29 and a 52-week high of $5.53. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock has a market cap of $78.75 million, a price-to-earnings ratio of -0.22 and a beta of 0.76. The business has a fifty day moving average of $0.45 and a two-hundred day moving average of $0.74.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The business had revenue of $18.57 million for the quarter. As a group, research analysts anticipate that bluebird bio will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On bluebird bio

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in bluebird bio by 458.8% during the 1st quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock worth $102,000 after buying an additional 65,710 shares during the last quarter. Vanguard Group Inc. lifted its stake in bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares during the last quarter. American International Group Inc. boosted its holdings in bluebird bio by 77.4% in the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 41,177 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in bluebird bio during the first quarter worth approximately $52,000. 87.43% of the stock is owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.